Skip to main content

Advertisement

Table 4 Unadjusted potential predictors of RBV adherence among the study population with available RBV adherence data (n = 86)

From: Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

  RBV adherence of 95% (%; n = 59) RBV adherence of < 95% (%; n = 27) Unadjusted OR 95% CI P
Age (years)
  ≤ 41 29 (66) 15 (34) 1.00 - -
  > 41 30 (71) 12 (29) 1.25 0.50–3.11 0.632
Gender
 Female 49 (69) 22 (31) 1.00 - -
 Male 10 (67) 5 (33) 1.14 0.35–3.72 0.833
Educationa
  < Tertiary 43 (69) 19 (31) 1.00 - -
 Tertiary or greater 15 (71) 6 (29) 1.18 0.40–3.48 0.766
Social functioning score
  < 17 29 (76) 9 (24) 1.00 - -
  ≥ 17 30 (63) 18 (38) 0.53 0.21–1.38 0.195
Current depressionb
 No 24 (65) 13 (35) 1.00 - -
 Yes 30 (68) 14 (32) 1.11 0.44–2.80 0.818
Hazardous alcohol consumptionc
 No 48 (68) 23 (32) 1.00 - -
 Yes 8 (67) 4 (33) 0.94 0.26–3.44 0.924
Current OST
 No 16 (64) 9 (36) 1.00 - -
 Yes 43 (70) 18 (30) 1.26 0.48–3.36 0.638
Injecting (last month)
 No 22 (69) 10 (31) 1.00 - -
 Yes 37 (69) 17 (31) 0.95 0.37–2.42 0.908
Frequency of injecting (last month)
 Never 22 (69) 10 (31) 1.00 - -
 Less than weekly 14 (67) 7 (33) 0.87 0.27–2.81 0.815
 Weekly or greater 23 (70) 10 (30) 1.00 0.35–2.86 1.000
Heroin injecting (last month)
 No 35 (66) 18 (34) 1.00 - -
 Yes 24 (73) 9 (27) 1.33 0.51–3.46 0.554
Cocaine injecting (last month)
 No 52 (68) 24 (32) 1.00 - -
 Yes 7 (70) 3 (30) 0.77 0.25–4.44 0.940
Amphetamine injecting (last month)
 No 51 (69) 23 (31) 1.00 - -
 Yes 8 (67) 4 (33) 0.88 0.24–3.24 0.853
Injecting on therapy
 No 25 (74) 9 (26) 1.00 - -
 Yes 34 (65) 18 (35) 0.65 0.25–1.69 0.380
Therapy duration
 24 weeks 18 (72) 7 (28) 1.00 - -
 12 weeks 41 (67) 20 (33) 0.80 0.29–2.22 0.664
  1. aMissing data for three participants
  2. bMissing data for five participants
  3. cMissing data for three participants; percentages refer to row percentages